NPI - Creating effective therapeutics.

Neuroprotect, Inc. (NPI) is a privately held, biopharmaceutical company focused on the development of proprietary platforms and first-in-class therapeutics for underserved CNS indications. Key assets include three lead compounds developed from two proprietary platforms: NPI-503 for prophylactic neuroprotection in patients at increased risk of ischemic brain injury (IBI) in the setting of cardiovascular surgery, NPI-505 for the treatment of acute IBI, and NPI-507 for the treatment of epilepsy and seizures.